Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc. - Common Stock
(NQ:
APVO
)
0.5160
-0.4141 (-44.52%)
Streaming Delayed Price
Updated: 10:43 AM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptevo Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Today 8:05 EST
Via
ACCESS Newswire
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
December 09, 2025
Via
ACCESS Newswire
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
November 10, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
November 06, 2025
Via
ACCESS Newswire
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
October 08, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
February 15, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 14, 2025
Via
ACCESS Newswire
TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
September 16, 2025
Via
AB Newswire
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
September 16, 2025
Via
ACCESS Newswire
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
September 05, 2025
Via
ACCESS Newswire
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
September 04, 2025
Via
ACCESS Newswire
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
August 13, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
August 11, 2025
Via
ACCESS Newswire
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 08, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 20, 2025
Via
ACCESS Newswire
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
June 20, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
June 18, 2025
Via
ACCESS Newswire
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
June 18, 2025
Via
ACCESS Newswire
Aptevo Participating in the BIO International Convention
June 13, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
May 22, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
May 14, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
May 08, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 22, 2025
Via
ACCESS Newswire
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 21, 2025
Via
ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 04, 2025
Via
ACCESS Newswire
$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
April 03, 2025
Via
AB Newswire
Topics
Intellectual Property
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 03, 2025
Via
ACCESS Newswire
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
March 20, 2025
Via
ACCESS Newswire
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
March 18, 2025
Via
ACCESS Newswire
Aptevo to Participate in March Conferences
March 06, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
